Problems and perspectives of phenotyping for drug-metabolizing enzymes in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 1, 2000, Pages 1-9

  Zaigler, M ^a   Tantcheva Poor I ^a   Fuhr, U ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

CYP1A2; CYP3A4; Cytocrome P 450; Drug metabolism; Phenotyping

Indexed keywords

CYTOCHROME P450 3A; DAPSONE; ERYTHROMYCIN; HYDROCORTISONE; LIDOCAINE; MIDAZOLAM; NIFEDIPINE; PHENACETIN O DEETHYLASE;

ARTICLE; DRUG DISPOSITION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; PHENOTYPE;

EID: 0033977305     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38001     Document Type: Article

References (63)

1. Aoyama T, Yamano S, Waxman DJ, Lepenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ 1989 Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264: 10388-10395
2. Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot MH, Menez JF 1995 Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 5: 72-79
3. Brockmoeller J, Roots I 1994 Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 27: 216-248
4. Brockmoller J, Roots I 1994 Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 27: 216-248
5. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ 1996 The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60: 522-534
6. Cheng WS, Murphy TL, Smith MT, Cooksley WG, Halliday JW, Powell LW 1990 Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clin Pharmacol Ther 47: 516-524
7. Daly AK 1995 Molecular basis of polymorphic drug metabolism. J Mol Med 73: 539-553
8. Denaro CP, Wilson M, Jacob P 3d, Benowitz NL 1996 The effect of liver disease on urine caffeine metabolite ratios. Clin Pharmacol Ther 59: 624-635
9. Denaro CP, Wilson M, Jacob P 3rd, Benowitz NL 1996 The effect of liver disease on urine caffeine metabolite ratios. Clin Pharmacol Ther 59: 624-635
10. Diasio RB, Beavers TL, Carpenter JT 1988 Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51
11. Ducharme J, Abdullah S, Wainer IW 1996 Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678: 113-128
12. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ 1979 Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183-187
13. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, Demard F 1992 Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902
14. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB 1996 The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 23: 1429-1435
15. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA 1997 Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62: 365-376
16. Fuhr U 1994 The use of caffeine metabolism to monitor liver function. In: Holoman J et al (ed) Book of Abstracts of the 1st International Symposium on Hepatology and Clinical Pharmacology: Liver and Drugs. Bratislava, Slovakia, 15
17. Fuhr U, Rost KL 1994 Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4: 109-116
18. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH 1996 Evaluation of caffeine as a test drug for CYP1A2, NAT2, CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6: 159-176
19. Gill HJ, Tingle MD, Park BK 1995 N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40: 531-538
20. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M 1998 Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26
21. Guengerich 1995 Cytochrome P450. Ortiz de Montellano, Plenum Press, NY, pp 473-535
22. Hong JY, Yang CS 1997 Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ Health Perspect 105 (Suppl 4): 759-762
23. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT Jr, Guzelian PS 1992 Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51: 18-23
24. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S et al 1992 The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 2: 246-258
25. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD 1996 Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 60: 374-384
26. Jover R, Carnicer F, Sànchez-Payà J, Climent E, Sirvent M, Marco JL 1997 Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol 92: 1905-1908
27. Kadlubar FF, Butler MA, Kaderlink KR, Chou HC, Lang NP 1992 Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 95: 69-74
28. Kalow W, Tang BK 1993 The use of caffeine for enzyme assays: A critical appraisal. Clin Pharmacol Ther 53: 503-514
29. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, Wilkinson GR, Wood AJ 1993 Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 54: 621-629
30. Kolars JC, Awni WM, Merion RM, Watkins PB 1991 First-pass metabolism of cyclosporin by the gut. Lancet 338: 1488-1490
31. Koley AP, Buters JT, Robinson RC, Markowitz A, Friedman FK 1995 CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers. J Biol Chem Mar 10: 5014-5018
32. Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB 1999 In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 66: 40-50
33. Lennard L, Welch JC, Lilleyman JS 1997 Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 44: 455-461
34. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB 1992 The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 51: 229-238
35. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB 1994 Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22: 947-955
36. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL 1977 Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-586
37. Min DI, Ku YM, Vichiendilokkul A, Fleckenstein LL 1999 A urine-metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. Pharmacotherapy 19: 753-759
38. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW 1996 Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 39: 65-69
39. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW 1995 Caffeine as a metabolic probe: a comparison of the metabolic ratio used to assess CYP1A2 activity. Br J Clin Pharmacol 39: 65-69
40. Parker AC, Pritchard P, Preston T, Choonara I 1998 Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 45: 176-178
41. Pollock BG 1994 Recent developments in drug metabolism of relevance to psychiatrists. Harv Rev Psychiatry 2: 204-213
42. Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T 1998 The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Br J Clin Pharmacol 46: 535-539
43. Rost KL, Roots I 1994 Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 55: 402-411
44. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT 1996 Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 6: 121-149
45. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI 1997 Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 18: 227-240
46. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI 1997 Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Br J Clin Pharmacol 40: 531-538
47. Schuetz JD, Beach DL, Guzelin PS 1994 Selective expression of cytochrome CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4: 11-20
48. Sesardic D, Boobis AR, Edwards RJ, Davies DS 1988 A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26: 363-372
49. Shrestha R, McKinley C, Showalter R, Wilner K, Marsano L, Vivian B, Everson G 1997 Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis. Liver Transplant Surg 3: 166-173
50. Silas JH, Lennard MS, Tucker GT, Smith AJ, Malcolm SL, Marten TR 1977 Why hypertensive patients vary in their response to oral debrisoquine. Br Med J 1: 422-425
51. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E 1997 Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 51: 395-398
52. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ 1996 Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 59: 47-51
53. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJ 1996 Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 59: 47-51
54. Tang BK, Zhou Y, Kadar D, Kalow W 1994 Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 4: 117-124
55. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL 1994 Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271: 549-556
56. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR 1996 Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59: 491-502
57. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP 1997 Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36: 370-381
58. Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E 1998 Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 26: 110-114
59. Watkins 1998 The CYP3A family: Extrahepatic tissue distribution and role. In: Maurel P et al (eds) Book of abstracts of the 12th International Symposium on Microsomes and Drug Oxidations. Montpellier, France, PL2-3
60. Watkins PB 1994 Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4: 171-184
61. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ 1990 The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48: 120-129
62. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ 1990 The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48: 120-129
63. Wrighton SA, Brian SA, Sari MA et al 1990 Studies on the expression and metabolic capacities of human liver cytochrome p450IIIA5 (HLp3). Mol Pharmacol 38: 207-213